These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Neuromodulation and the Gut-Brain Axis: Therapeutic Mechanisms and Implications for Gastrointestinal and Neurological Disorders. Aljeradat B; Kumar D; Abdulmuizz S; Kundu M; Almealawy YF; Batarseh DR; Atallah O; Ennabe M; Alsarafandi M; Alan A; Weinand M Pathophysiology; 2024 May; 31(2):244-268. PubMed ID: 38804299 [TBL] [Abstract][Full Text] [Related]
4. Recent advancements in nanoparticle based drug delivery for gastrointestinal disorders. Mittal R; Patel AP; Jhaveri VM; Kay SS; Debs LH; Parrish JM; Pan DR; Nguyen D; Mittal J; Jayant RD Expert Opin Drug Deliv; 2018 Mar; 15(3):301-318. PubMed ID: 29272976 [TBL] [Abstract][Full Text] [Related]
8. Gene therapy for inherited retinal diseases: exploiting new tools in genome editing and nanotechnology. Carvalho C; Lemos L; Antas P; Seabra MC Front Ophthalmol (Lausanne); 2023; 3():1270561. PubMed ID: 38983081 [TBL] [Abstract][Full Text] [Related]
9. Gene therapy for polygenic or complex diseases. Wu T; Hu Y; Tang LV Biomark Res; 2024 Sep; 12(1):99. PubMed ID: 39232780 [TBL] [Abstract][Full Text] [Related]
10. Extracellular Vesicles as Drug Delivery System for Cancer Therapy. Wang J; Yin B; Lian J; Wang X Pharmaceutics; 2024 Aug; 16(8):. PubMed ID: 39204374 [TBL] [Abstract][Full Text] [Related]
11. Advancements in Hematopoietic Stem Cell Gene Therapy: A Journey of Progress for Viral Transduction. Giommetti A; Papanikolaou E Cells; 2024 Jun; 13(12):. PubMed ID: 38920667 [TBL] [Abstract][Full Text] [Related]
12. Prospective therapeutic targets and recent advancements in the treatment of inflammatory bowel disease. Sinha A; Roy S Immunopharmacol Immunotoxicol; 2024 Aug; 46(4):550-563. PubMed ID: 39013809 [TBL] [Abstract][Full Text] [Related]
13. Site-specific genome editing in treatment of inherited diseases: possibility, progress, and perspectives. Huang C; Li Q; Li J Med Rev (2021); 2022 Oct; 2(5):471-500. PubMed ID: 37724161 [TBL] [Abstract][Full Text] [Related]
14. Emerging strategies for treating autoimmune disease with genetically modified dendritic cells. Ma Y; Shi R; Li F; Chang H Cell Commun Signal; 2024 May; 22(1):262. PubMed ID: 38715122 [TBL] [Abstract][Full Text] [Related]
16. Insect pathogens as biological control agents: Back to the future. Lacey LA; Grzywacz D; Shapiro-Ilan DI; Frutos R; Brownbridge M; Goettel MS J Invertebr Pathol; 2015 Nov; 132():1-41. PubMed ID: 26225455 [TBL] [Abstract][Full Text] [Related]
17. The future of Cochrane Neonatal. Soll RF; Ovelman C; McGuire W Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834 [TBL] [Abstract][Full Text] [Related]
18. Oral delivery of micro/nanoparticulate systems based on natural polysaccharides for intestinal diseases therapy: Challenges, advances and future perspectives. Dos Santos AM; Carvalho SG; Meneguin AB; Sábio RM; Gremião MPD; Chorilli M J Control Release; 2021 Jun; 334():353-366. PubMed ID: 33901582 [TBL] [Abstract][Full Text] [Related]
19. The future of nanomedicine in optimising the treatment of inflammatory bowel disease. Mohan LJ; Daly JS; Ryan BM; Ramtoola Z Scand J Gastroenterol; 2019 Jan; 54(1):18-26. PubMed ID: 30678499 [TBL] [Abstract][Full Text] [Related]
20. The advancements and prospective developments in anti-tumor targeted therapy. Leng G; Duan B; Liu J; Li S; Zhao W; Wang S; Hou G; Qu J Neoplasia; 2024 Oct; 56():101024. PubMed ID: 39047659 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]